<DOC>
	<DOC>NCT00141479</DOC>
	<brief_summary>The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.</brief_summary>
	<brief_title>To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Diagnosis of Schizophrenia or Schizoaffective disorder 1855 years Subjects who are acutely psychotic Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia Subjects at significant risk of suicide Subjects with a seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Treatment interruption on reinitiation</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
</DOC>